GCC Nurse — Fibromyalgia & CFS Guide

What is Fibromyalgia?

Fibromyalgia (FM) is a chronic widespread pain disorder characterised by central sensitisation — amplified pain processing within the central nervous system without peripheral inflammation or structural pathology. It is the prototype of nociplastic pain.

Core Features

Widespread musculoskeletal pain — bilateral, above and below waist
Chronic fatigue — often debilitating
Unrefreshing sleep (non-restorative sleep)
Cognitive impairment — "fibro fog" (poor concentration, memory)
Duration: typically >3 months

Common Comorbidities

Irritable bowel syndrome (IBS) — 30–70%
Headaches / migraine
Anxiety and depression
Sensory hypersensitivity (noise, light, temperature)
Interstitial cystitis / chronic pelvic pain
Temporomandibular joint disorder

Epidemiology FM affects 2–4% of the general population globally. Female:male ratio approximately 7–9:1. Peak onset 30–50 years. GCC studies report prevalence of 3–5%; commonly underdiagnosed and misattributed to psychiatric disorder or "unexplained somatic complaints."

Pathophysiology — Central Sensitisation

FM is not a disease of peripheral tissues. The hallmark is central sensitisation: hyperexcitability of the CNS pain-processing pathways leading to amplified pain signals.

Key Mechanism

Overactivation of NMDA receptors in dorsal horn
Elevated substance P in cerebrospinal fluid
Reduced descending inhibitory control (serotonin, noradrenaline deficit)
Abnormal pain wind-up and temporal summation

Neuroimaging Evidence

fMRI: enhanced activation in pain-processing regions
Reduced blood flow in thalamus and caudate nucleus
Altered default mode network connectivity
Supports biological, not psychological, origin

Genetics & Triggers

First-degree relatives: 8× higher risk
COMT gene polymorphisms implicated
Triggers: physical trauma, infection, major life stress
Post-COVID FM presentations increasing

Clinical Implication Because FM is driven by central sensitisation — NOT peripheral inflammation — opioids and NSAIDs are largely ineffective and may worsen outcomes. Management targets CNS modulation.

ACR Diagnostic Criteria — 2010/2016 Revision

The American College of Rheumatology (ACR) 2010 criteria revised in 2016 removed the historical 18 tender-point examination. Diagnosis is now symptom-based.

Exam Point: No Tender Point Test Required (2010 onwards) The 18 tender-point physical examination is no longer required for diagnosis. The 2010/2016 criteria use Widespread Pain Index (WPI) and Symptom Severity (SS) scale.

Diagnostic Criteria (must meet ALL three)

Criterion	Details
1. WPI + SS Threshold	WPI ≥7 AND SS score ≥5 OR WPI 4–6 AND SS score ≥9
2. Symptom Duration	Symptoms present at similar level for ≥3 months
3. No Better Explanation	Pain not better explained by another diagnosis

Widespread Pain Index (WPI) — 0 to 19

Patient indicates which of 19 body regions had pain in the last week. Score = number of regions. Regions include: jaw (L/R), shoulder girdle (L/R), upper arm (L/R), lower arm (L/R), hip/buttock/trochanter (L/R), upper leg (L/R), lower leg (L/R), chest, abdomen, upper back, lower back, neck.

Symptom Severity (SS) Scale — 0 to 12

Part 1: Severity (0–3 each) — max 9 points

Fatigue
Waking unrefreshed
Cognitive symptoms
(0=no problem, 1=slight, 2=moderate, 3=severe)

Part 2: Somatic Symptoms — max 3 points

0 = no symptoms
1 = few symptoms
2 = moderate number
3 = many symptoms (e.g., IBS, headache, fatigue, dizziness)

Differential Diagnosis — Ruling Out Other Conditions

FM is a diagnosis of positive criteria, not purely exclusion, but key differentials must be considered:

Condition	Distinguishing Features	Investigations
Inflammatory Arthritis (RA, SpA)	Joint swelling, morning stiffness >1 hr, asymmetric joints	ESR, CRP, RF, anti-CCP, X-ray
Hypothyroidism	Weight gain, cold intolerance, constipation, bradycardia	TSH, Free T4
SLE / CTD	Rash, serositis, renal involvement, photosensitivity	ANA, anti-dsDNA, complement
Polymyalgia Rheumatica	Age >50, shoulder/hip girdle stiffness, dramatic steroid response	ESR (often >50), CRP
Inflammatory Myopathy	Proximal muscle weakness (not just pain), elevated CK	CK, LDH, EMG, muscle biopsy
Sleep Apnoea	Snoring, witnessed apnoea, obesity, daytime somnolence	Polysomnography / sleep study

Key: FM + Inflammatory Disease Can Coexist FM frequently occurs alongside RA, lupus, and ankylosing spondylitis. The presence of an inflammatory condition does not exclude FM — and FM pain should not be attributed to the inflammatory disease without assessment.

GCC Context — Underdiagnosis & Stigma

FM is frequently misdiagnosed or dismissed as a psychiatric/psychosomatic condition in GCC healthcare systems
Patients often undergo extensive — and expensive — investigations before FM is considered
High frequency of emergency department visits and specialist consultations before diagnosis
Cultural perception: "pain without cause" may be viewed as weakness, malingering, or exaggeration
Female patients in conservative settings may face additional barriers disclosing psychosocial symptoms
Nurses play a critical role in validation — acknowledging the reality of the patient's experience

ME/CFS — Definition & Overview

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a complex, disabling multisystem illness characterised by profound fatigue that is not relieved by rest and is made significantly worse by physical or cognitive exertion.

Post-Exertional Malaise (PEM) — The Hallmark Feature PEM is the cardinal and distinguishing feature of ME/CFS. Symptoms typically flare 12–72 hours after activity and can last days to weeks. This is NOT normal fatigue. Nurses must explicitly ask about PEM — patients often do not volunteer it.

Core Features (NICE 2021 Criteria)

Debilitating fatigue — duration ≥6 months
Post-exertional malaise (PEM)
Unrefreshing sleep — sleep does not restore energy
Cognitive impairment — brain fog, concentration, memory
Orthostatic intolerance
All features substantially reduce function vs pre-illness

Additional Common Symptoms

Muscle and joint pain without swelling
Headaches (new type, different from pre-illness)
Sensory sensitivities (light, noise, smell)
Sore throat / tender lymph nodes
Dizziness, palpitations (POTS)
Temperature dysregulation
Nausea, gastrointestinal symptoms

Diagnostic Criteria — Canadian Consensus & NICE 2021

Criteria Set	Key Requirements
NICE 2021	All of: (1) debilitating fatigue ≥3 months in adults (≥4 weeks in children), (2) PEM, (3) unrefreshing sleep — plus at least one of: cognitive impairment or orthostatic intolerance. Diagnosis at 3 months (not 6).
Canadian Consensus Criteria (CCC 2003)	Fatigue ≥6 months + PEM + sleep dysfunction + pain + ≥2 neurological/cognitive + ≥1 autonomic/neuroendocrine/immune symptom
International Consensus Criteria (ICC 2011)	Prefers "ME" — stricter criteria emphasising neurological, immune, and energy production impairments; PEM required

Diagnosis is Clinical — No Biomarker Exists ME/CFS has no diagnostic blood test or scan. Diagnosis requires systematic clinical assessment and exclusion of treatable conditions. Investigations should rule out: anaemia, thyroid disease, diabetes, liver/renal disease, sleep disorders, depression.

Post-Exertional Malaise (PEM) — Nursing Understanding

What is PEM?

PEM is a worsening of all ME/CFS symptoms following physical, cognitive, emotional, or sensory exertion. The delay (12–72 hours) means patients often do not connect the exertion with the crash. This leads to repeated cycles of overdoing then crashing — the boom-bust cycle.

PEM Triggers

Physical activity (walking, exercise, housework)
Cognitive effort (reading, conversations, screens)
Emotional stress
Sensory overload (bright lights, crowded spaces)
Temperature extremes
Infections / vaccinations

PEM Symptoms

Extreme exhaustion / "collapse"
Muscle weakness, tremors
Worsening brain fog
Pain amplification
Flu-like symptoms
Inability to get out of bed

Critical: Do NOT Push Through PEM Advising patients with ME/CFS to "push through" fatigue, use graded exercise therapy (GET), or "exercise more" can cause significant — sometimes permanent — deterioration. Pacing is the correct approach.

Pacing — The Core Management Strategy for ME/CFS

Energy Envelope Theory

Each ME/CFS patient has a limited energy "envelope." Activities must stay within this envelope to avoid PEM. The goal is to establish a stable baseline — not to push beyond it.

Pacing Principles

Plan activity at 50–70% of what feels possible on a good day
Rest before becoming exhausted — proactive, not reactive rest
Break activities into small chunks with rest intervals
Keep a pacing diary to identify triggers and limits
Avoid "boom days" — overdoing on good days
Gradual, very slow increase in activity only when stable ≥4 weeks

Pacing vs Graded Exercise Therapy

	Pacing	GET
Suitable for	ME/CFS	FM (not ME/CFS)
Principle	Stay within energy envelope	Progressive increase in activity
PEM risk	Minimises PEM	Can trigger PEM in ME/CFS
NICE 2021	Recommended	Not recommended for ME/CFS

Orthostatic Intolerance & POTS

Orthostatic intolerance — symptoms worsened by upright posture — is common in ME/CFS (up to 97% in some studies). The most recognised form is Postural Orthostatic Tachycardia Syndrome (POTS).

POTS Diagnostic Features

Heart rate increase ≥30 bpm within 10 minutes of standing (or ≥40 bpm in under-19s)
Without sustained hypotension (>20 mmHg SBP drop)
Symptoms: dizziness, pre-syncope, palpitations, nausea
Confirmed by: NASA lean test or tilt table test

Nursing Management of POTS

Increase salt and fluid intake (if appropriate)
Compression stockings (thigh-high preferred)
Elevate head of bed 10–30 degrees
Rise slowly — sit before standing, stand before walking
Avoid prolonged standing, hot showers, large meals
Beta-blockers, fludrocortisone — prescriber decision

ME/CFS Assessment Tools

Tool	Purpose	Scoring
SF-36	Health-related quality of life — physical and mental component scores; ME/CFS shows specific pattern: low physical, relatively higher mental	0–100 per domain; higher = better function
Fatigue Severity Scale (FSS)	9 items; fatigue impact on daily functioning	1–7 per item; mean ≥4 = significant fatigue
Bell Disability Scale	ME/CFS-specific; overall functional capacity	0–100; 0=severely ill, 100=fully functional
DePaul Symptom Questionnaire	Comprehensive ME/CFS symptom frequency and severity	Multi-domain

ME/CFS and Long COVID

Long COVID — symptoms persisting >12 weeks after acute COVID-19 — shows substantial overlap with ME/CFS. Studies indicate 30–58% of Long COVID patients meet ME/CFS diagnostic criteria.

Shared Features

Post-exertional malaise
Unrefreshing sleep
Cognitive impairment / brain fog
Orthostatic intolerance / POTS
Immune dysregulation

GCC Clinical Context

Long COVID now accepted diagnosis in GCC healthcare systems
ME/CFS criteria should be applied to Long COVID patients with appropriate features
Pacing remains the safest approach for Long COVID PEM
Avoid recommending graded exercise for Long COVID with PEM

GCC Context — ME/CFS Diagnosis Gap ME/CFS is rarely formally diagnosed in GCC countries. Patients are frequently labelled as having depression, anxiety disorder, or functional somatic syndrome. Nurses and clinicians should recognise PEM as the key differentiating feature.

Patient Education — The Essential First Step

Validation is Therapeutic The single most important initial intervention in FM/ME/CFS is acknowledging and validating the patient's experience. Many patients have been told their symptoms are "all in their head" — correcting this misperception begins the therapeutic relationship.

Key Education Points for FM Patients

FM is a real biological condition — caused by amplified CNS pain processing
It is not a psychiatric disorder, although mood is affected
Normal investigations (no joint damage, normal blood tests) are reassuring — not dismissive
Treatment focuses on improving function and quality of life, not "cure"
Active patient participation is essential — self-management is central
Prognosis: waxing and waning — flares are not permanent worsening

Exercise & Physical Activity

FM — Graded Aerobic Exercise

Strongest evidence base for FM management
Aerobic exercise 2–3×/week; 20–30 min sessions
Start low, go slow — 5–10 minutes, increase by 2 min/week
Low-impact preferred: walking, swimming, cycling, yoga
Expect initial pain increase — reassure patient this is temporary
Resistance training also beneficial; combination most effective

ME/CFS — Pacing (NOT GET)

Graded Exercise Therapy (GET) is contraindicated in ME/CFS
NICE 2021 explicitly removed GET recommendation for ME/CFS
Activity should remain within individual energy envelope
Heart Rate monitoring: keep HR below anaerobic threshold (~50–60% max HR)
Gentle stretching and range-of-motion within tolerance
Goal: stability and gradual extension — not progressive loading

FM vs ME/CFS — Opposite Exercise Approaches FM benefits from graduated aerobic exercise. ME/CFS requires pacing within energy limits. Misapplying graded exercise to ME/CFS can cause serious harm. Always clarify diagnosis before recommending exercise.

Hydrotherapy & Aquatic Therapy

Warm water reduces muscle tension, buoyancy decreases joint load, and hydrostatic pressure provides sensory input that modulates pain. Evidence-based for FM.

Water temperature 32–36°C (cooler than typical hydrotherapy for some other conditions)
Sessions 30–45 minutes, 2–3×/week
Combines gentle aerobic exercise with relaxation
Particularly accessible in GCC given warm climate — outdoor warm pools, hydrotherapy centres in hospitals
Benefits: pain reduction, improved sleep, reduced anxiety, functional improvement

Cognitive Behavioural Therapy (CBT)

CBT is among the best-evidenced psychological interventions for both FM and ME/CFS. Targets unhelpful thought patterns and behaviours that perpetuate pain and disability.

CBT Targets in FM/ME/CFS

Pain catastrophising: Reducing rumination, magnification, and helplessness thoughts
Fear-avoidance: Addressing kinesiophobia and activity avoidance in FM
Boom-bust cycle: Understanding and managing energy fluctuations (especially ME/CFS)
Sleep: CBT-I (Cognitive Behavioural Therapy for Insomnia) is first-line for sleep disturbance
Illness beliefs: Working with unhelpful beliefs about activity and health

Note on CBT in ME/CFS CBT for ME/CFS (when based on a deconditioning model) is controversial and no longer recommended as a standalone treatment by NICE 2021. CBT can address comorbid anxiety, depression, and sleep problems, but should not be offered with the message that ME/CFS is a psychological disorder.

Sleep Hygiene & Management

Non-restorative sleep is universal in FM and ME/CFS — it both causes and perpetuates symptoms. Sleep management is a core therapeutic target.

Sleep Hygiene Principles

Consistent sleep/wake times — including weekends
Avoid caffeine after 2pm (consider earlier if very sensitive)
Cool, dark, quiet bedroom environment
No screens 60 minutes before bed (blue light suppresses melatonin)
Avoid heavy meals within 2–3 hours of bed
Relaxation routine — progressive muscle relaxation, mindfulness
Bed is for sleep and sex only — not work, TV, phone

Sleep Restriction Therapy (SRT)

Component of CBT-I
Restrict time in bed to estimated actual sleep time initially
Builds sleep pressure and consolidates sleep
Gradually extend sleep window as efficiency improves
Supervised by trained therapist or nurse
Effective for sleep initiation and maintenance insomnia

Mindfulness & Psychological Therapies

Mindfulness-Based Stress Reduction (MBSR)

8-week structured programme (Kabat-Zinn model)
Body scan, breath awareness, mindful movement
Reduces pain catastrophising
Improves mood, sleep quality, and pain tolerance
Growing evidence base for FM specifically

Acceptance and Commitment Therapy (ACT)

Focuses on psychological flexibility — not elimination of pain
Patients learn to live a meaningful life alongside pain
Reduces suffering and avoidance behaviours
Evidence emerging as at least equivalent to CBT in chronic pain

Multidisciplinary Pain Programme (MPP)

The most effective management for FM is a comprehensive multidisciplinary approach combining medical, psychological, and physical components in an integrated programme.

Team Member	Role
Pain physician / Rheumatologist	Diagnosis, medication management, coordination
Physiotherapist	Graded exercise programme, hydrotherapy, pacing education
Psychologist / Therapist	CBT, ACT, MBSR, sleep therapy
Occupational Therapist	ADL modification, work assessment, energy conservation
Specialist Nurse	Education, coordination, self-management support, psychosocial assessment
Social Worker	Disability assessment, return-to-work, financial advice

Pharmacological Overview

Realistic Expectations No medication "cures" FM. Pharmacological treatment aims for partial benefit: 30–50% reduction in symptoms is considered meaningful. Set trial periods of 4–6 weeks. If no benefit, discontinue and try an alternative. Medication is adjunctive — non-pharmacological approaches remain primary.

Antidepressants in FM

Used for CNS pain modulation — not primarily for depression (though frequently comorbid). Effects are separate from antidepressant action.

Drug	Class	Dose	Mechanism / Notes
Amitriptyline	TCA	10–25 mg nocte (up to 75 mg)	Na-channel blockade, descending pain modulation, improves sleep. Most evidence for FM. Low dose — not antidepressant dose. Side effects: dry mouth, constipation, weight gain, sedation. Avoid in cardiac conduction abnormalities.
Duloxetine	SNRI	30–60 mg/day (max 120 mg)	FDA-approved for FM. Inhibits serotonin + noradrenaline reuptake — enhances descending inhibition. Also treats comorbid depression/anxiety. Side effects: nausea (take with food), insomnia, hypertension.
Milnacipran	SNRI	12.5 mg start → 50 mg BD (max 200 mg/day)	FDA and EMA approved for FM. Stronger noradrenaline effect than duloxetine. Not widely available in GCC. Side effects: similar to duloxetine; dysuria in men.
Venlafaxine	SNRI	37.5–150 mg/day	Off-label for FM. Evidence weaker than duloxetine. Useful when depression predominant.

Anticonvulsants / Gabapentinoids

Drug	Dose	Notes
Pregabalin	75 mg BD → 150–225 mg BD (max 450 mg/day)	FDA-approved for FM. Reduces calcium channel-mediated neurotransmitter release in spinal cord. Benefits: pain, sleep, anxiety. Side effects: sedation, dizziness, weight gain, peripheral oedema. Dependence risk — scheduled in many countries. Titrate slowly.
Gabapentin	300 mg OD → 300–600 mg TDS (max 2400 mg/day)	Not FDA-approved for FM but used off-label. Similar mechanism to pregabalin. Less predictable absorption. Similar side effect profile. Multiple daily dosing required.

Dependence & Misuse Risk Both pregabalin and gabapentin carry dependence and misuse potential. In GCC countries, pregabalin is a scheduled/controlled substance in Saudi Arabia, UAE, and Qatar. Review regularly. Avoid abrupt withdrawal — taper gradually over weeks.

Medications to AVOID in FM

Strong Opioids — Contraindicated in FM Strong opioids (morphine, oxycodone, fentanyl) worsen central sensitisation and are ineffective for FM pain. They increase pain hypersensitivity over time (opioid-induced hyperalgesia), cause dependence, and have significant side effects. NICE, EULAR, and ACR guidelines do NOT recommend opioids for FM.

Drug / Class	Reason to Avoid
Strong opioids (morphine, oxycodone, fentanyl)	Worsen central sensitisation; no evidence of benefit; dependence risk; opioid-induced hyperalgesia
Corticosteroids	Not effective in FM (no inflammation). Significant harm with prolonged use. Do not confuse with polymyalgia.
NSAIDs alone	Limited benefit as monotherapy. Useful only as adjunct. GI, cardiovascular, renal risks with prolonged use.
Benzodiazepines	Risk of dependence; worsen sleep architecture; cognitive impairment. Short-term only if absolutely needed.

Tramadol — Limited Role Tramadol is sometimes used short-term in FM (weak opioid + serotonin/noradrenaline reuptake inhibition). Evidence is limited. Risks: dependence, serotonin syndrome (especially with SNRIs), seizures (lowers seizure threshold). If used, short-term only and not with SNRIs.

Topical & Other Agents

Agent	Dose / Route	Notes
Capsaicin cream	0.025–0.075% cream; apply 3–4×/day to painful areas	Depletes substance P in peripheral nerve endings. Initial burning on application — warn patient. Avoid mucous membranes. Useful for localised FM pain areas.
Lidocaine patches	5% patch; apply 12 hours on / 12 hours off	Localised pain relief. Limited systemic absorption. Evidence mainly for postherpetic neuralgia; used off-label in localised FM.
Melatonin	0.5–5 mg nocte	Improves sleep onset and quality. Safe long-term. Over-the-counter in some GCC countries. First-line sleep aid in FM.
Low-dose quetiapine	12.5–50 mg nocte	Used off-label for sleep and pain modulation. Sedation and weight gain. Not first-line. Useful when anxiety/depression prominent.
Zopiclone / Zolpidem	Zopiclone 3.75–7.5 mg nocte	Short-term sleep only (2–4 weeks). Dependence risk. Does not improve sleep architecture. Not recommended long-term in FM.

Polypharmacy Review

FM patients commonly accumulate multiple medications through multiple specialist consultations
Regular medication reviews are essential — at least every 6 months
Assess each drug: Is it still needed? Is it helping? What are the harms?
Deprescribing is a clinical skill — reduce burden, not just add medications
Drug interactions: watch for serotonin syndrome risk (SNRIs + tramadol + triptans)
GCC context: private sector prescribing practices can lead to extensive polypharmacy lists

Pain Assessment in FM/ME/CFS

Multidimensional Assessment

NRS (0–10): Pain intensity — but also assess quality and character
Quality descriptors: burning, aching, shooting, stabbing, "all over"
Diurnal variation: Worse in morning? After activity? At rest?
Functional impact: What can't the patient do because of pain?
Cognitive impact: Ask explicitly about memory, concentration, word-finding
Sleep quality: Refreshed on waking? Hours slept vs hours needed?

Key Screening Tools

PHQ-9: Depression screening — score ≥10 warrants review; high comorbidity in FM
GAD-7: Anxiety screening — score ≥10 moderate anxiety
Pain Catastrophising Scale (PCS): ≥30 = high catastrophising; refer for psychology
Fibromyalgia Impact Questionnaire Revised (FIQ-R): FM-specific quality of life
Fatigue Severity Scale (FSS): Mean ≥4 indicates significant fatigue

Functional & ADL Assessment

Assess basic ADLs: personal hygiene, dressing, meal preparation, mobility
Assess instrumental ADLs: shopping, driving, housework, finance management
Work ability: Is the patient working? Full-time/part-time? Sick leave frequency?
Assess social participation: isolation, hobbies, relationships with family and friends
Carer burden: Family members may take on caring role — assess their wellbeing
Use Occupational Therapy referral for formal functional capacity evaluation if work is affected

Invalidation Experiences & Therapeutic Communication

The Invalidation Problem Research shows that up to 80% of FM patients report having their symptoms dismissed or minimised by healthcare professionals. This is deeply harmful. Invalidation increases pain catastrophising, depression, and healthcare-seeking behaviour.

Common Invalidating Statements (Avoid)

"You look fine." / "Your tests are all normal."
"It's probably just stress." / "You need to relax more."
"There's nothing wrong with you." / "It's in your head."
"You just need to exercise more." / "Everyone gets tired."

Validating, Therapeutic Approach

"Your pain is real — your nervous system is amplifying pain signals, even without tissue damage."
"Normal investigations are actually good news — no damage, but we still need to treat your symptoms."
"I believe you. These conditions are genuinely difficult and poorly understood."
Acknowledge the diagnostic journey — "It can take years to get a diagnosis. That must have been exhausting."
Use shared decision-making — involve the patient in management choices

Self-Management Support

Tools & Techniques

Pacing diary: Record activities, rest periods, and symptoms to identify patterns
Symptom diary: Track pain, fatigue, sleep, mood daily — identifies triggers and trends
Flare management plan: Pre-agreed plan for what to do in a flare (rest protocol, who to contact, medication adjustments)
Goal setting: SMART goals — realistic activity targets that build confidence

Nurse-Led Education Topics

Understanding central sensitisation (patient-friendly explanation)
Sleep hygiene — personalised advice
Medication purpose and side effects
Pacing principles and energy envelope
Red flag symptoms requiring urgent review
Community resources and support groups

Work, Social & Financial Impact

FM and ME/CFS are leading causes of long-term sick leave and disability
Presenteeism (attending work while unwell) is as economically costly as absenteeism
Phased return to work: Gradual return with reduced hours, modified duties
Reasonable adjustments: Flexible start times, rest break schedule, ergonomic workstation, remote working where possible
Occupational therapy can produce formal functional capacity evaluation for employment purposes
Social work referral: financial advice, disability benefits, housing support, family mediation
Relationship strain: partner/family fatigue from caring; couple/family therapy referral if appropriate

GCC-Specific Nursing Considerations

Cultural & Religious Considerations

Chronic pain as diagnosis may not be culturally accepted — expectation of "cure" or single cause
Religious coping: Prayer, Quran recitation, and spiritual practices are valid and complementary pain coping strategies — do not dismiss
Involve family (particularly for female patients in conservative settings) in education when appropriate and with patient consent
Ramadan: medication timing adjustments needed; fasting may affect sleep and symptoms — proactive counselling

Practical Clinical Considerations

Female patient modesty: physiotherapy, hydrotherapy, and physical examination must accommodate cultural preferences — female physiotherapist, private gym/pool sessions
Arabic language resources: provide patient education materials in Arabic
Heat and humidity: high temperatures can worsen FM symptoms — patient education on activity planning in summer months
Vitamin D deficiency is endemic in GCC (sun avoidance, covering) — contributes to musculoskeletal pain; assess and supplement

Component	Threshold A	Threshold B
WPI (Widespread Pain Index)	≥7	4–6
SS (Symptom Severity)	≥5	≥9
Duration	≥3 months at similar level
No better explanation	Pain not explained by another disorder

Feature	Detail
Fatigue	≥6 months (NICE: ≥3 months); not relieved by rest; reduces function significantly
PEM (Post-Exertional Malaise)	HALLMARK — symptom flare 12–72 hours after activity; lasts days–weeks
Unrefreshing sleep	Does not restore energy regardless of duration
Cognitive impairment	Brain fog — memory, concentration, processing speed
Orthostatic intolerance	Symptoms worse on standing; POTS in many patients

	Pacing (ME/CFS)	Graded Exercise Therapy (FM)
Goal	Stabilise; remain within energy envelope	Progressively increase fitness and activity
PEM approach	Avoid and minimise PEM	PEM less of a concern (FM less severe)
NICE guidance	Recommended for ME/CFS; GET removed 2021	Exercise recommended for FM
Typical error	Applying GET to ME/CFS — can cause deterioration	Applying pacing-only to FM — misses exercise benefit

Drug	Class	FM	ME/CFS	Key Notes
Amitriptyline 10–25 mg nocte	TCA	First-line	Sleep/pain	Sleep + pain; low dose; cardiac caution
Duloxetine 30–60 mg/day	SNRI	FDA approved	Comorbid depression	Pain + mood; nausea initially
Pregabalin 75–225 mg BD	Gabapentinoid	FDA approved	Limited evidence	Sleep + pain; dependence risk; scheduled
Tramadol (short-term)	Weak opioid/SNRI	Short-term only	Avoid	Serotonin syndrome if with SNRIs
Strong opioids	Opioid	Avoid	Avoid	Worsens central sensitisation
NSAIDs	Anti-inflammatory	Adjunct only	Adjunct only	No evidence as monotherapy in FM
Melatonin 0.5–5 mg nocte	Chronobiotic	Sleep	Sleep	Safe; first-line sleep supplement